Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 3618: High-avidity BCMA CAR and high-affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJohn ReiserAOAlison O’ConnorBHBryan Hancock

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reiser et al. (2024) studied this question.

synapsesocial.com/papers/68e72cdcb6db6435876a6655https://doi.org/10.1158/1538-7445.am2024-3618
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1535: Preclinical evaluation of allogeneic BCMA/CD70 Dual CAR T cells for high-risk multiple myeloma2026
  2. 2Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma2025
  3. 3Abstract 1520: Improving BCMA-targeted CAR-T cell therapy of myeloma using TGF-β resistance and inducible production of IL-182026
  4. 4Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies2026
  5. 5Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025